Cord Blood-derived Expanded Allogeneic Natural Killer Cells

BIOLOGICAL3 trials

Sponsors

M.D. Anderson Cancer Center

Conditions

Mantle Cell LymphomaRecurrent Cutaneous MelanomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent GliosarcomaRecurrent Indolent Adult Non-Hodgkin LymphomaRecurrent Lip and Oral Cavity CarcinomaRecurrent Malignant Endocrine Neoplasm

Phase 1

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

TerminatedNCT03420963

M.D. Anderson Cancer CenterRecurrent Cutaneous Melanoma, Recurrent Lip and Oral Cavity Carcinoma, Recurrent Malignant Endocrine Neoplasm +25

Start: 2018-08-31End: 2026-02-26Updated: 2026-03-20

Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM

RecruitingNCT04991870

M.D. Anderson Cancer CenterRecurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma, Supratentorial Gliosarcoma

Start: 2023-04-28End: 2027-01-31Target: 25Updated: 2026-09-04

Phase 2

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

CompletedNCT03019640

M.D. Anderson Cancer CenterMantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma +4

Start: 2017-10-10End: 2021-08-16Updated: 2023-02-16

Related Papers

Recent Advancements in Cell-Based Therapies in Melanoma.

2024-09-124 citations

A phase 1 dose escalation trial of ex-vivo expanded allogeneic cord blood–derived natural killer cell immunotherapy for pediatric solid tumor malignancies.

Journal of Clinical Oncology2023-06-011 citations